Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Closed Posted
- Opportunity number
- RFA-CA-25-002
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $300,000
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- County Governments
- Higher Education Inst. (Public)
- Tribal Governments (Federally Recognized)
- City/Township Governments
- State Governments
- Non-501(c)(3) Nonprofits
- Special District Governments
- Public or Indian Housing Auth.
- Independent School Districts
- Tribal Organizations (Not Federally Recognized)
- For Profit Organizations
- Higher Education Inst. (Private)
- Small Businesses
- Other
- 501(c)(3) Nonprofits
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Cancer Institute (NCI) is soliciting R33 grant applications for advanced development and validation of emerging molecular and cellular analysis technologies focused on cancer research. The funding opportunity seeks exploratory research projects that have already overcome major feasibility gaps and possess preliminary data, with the goal of developing technologies that can accelerate research in cancer biology, early detection, screening, clinical diagnosis, treatment, and health disparities. Eligible applicants include higher education institutions, nonprofits, small businesses, tribal organizations, and various government entities. Proposed technologies must offer novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer, with a focus on improving molecular and/or cellular characterizations. The application must demonstrate potential for widespread applicability and must be part of the NCI's Innovative Molecular Analysis Technologies (IMAT) Program. The grant opportunity was posted on December 16, 2024, with a submission deadline of December 9, 2025.
While specific award amounts are not detailed in the grant announcement, the Cancer Detection and Diagnosis Research program historically awards grants ranging from $200,000 to nearly $3 million, with project periods typically spanning 2-5 years. The research is expected to be conducted at the recipient organization's facilities across the United States, with a strong emphasis on translational research that can potentially improve cancer detection, diagnosis, and patient outcomes. Projects will be evaluated based on scientific merit, program relevance, and potential for advancing cancer research technologies. The funding is administered through the Department of Health and Human Services/National Institutes of Health under the Cancer Detection and Diagnosis Research program (CFDA 93.394).
Synopsis
2 versions
Update #2 · Latest ·
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Update #1 ·
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Files
| File | Type | Posted |
|---|---|---|
| RFA-CA-25-002-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity